1057682-03-7

Basic information

• Product Name: (S)-6-(3-Methylpiperazin-1-yl)nicotinonitrile
• Synonyms: (S)-6-(3-Methylpiperazin-1-yl)nicotinonitrile;6-[(3S)-3-methylpiperazin-1-yl]pyridine-3-carbonitrile
• CAS NO: 1057682-03-7
• Molecular Formula: C₁₁H₁₄N₄
• Molecular Weight: 202.25566
• Mol File: 1057682-03-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: (S)-6-(3-Methylpiperazin-1-yl)nicotinonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-6-(3-Methylpiperazin-1-yl)nicotinonitrile(1057682-03-7)
• EPA Substance Registry System: (S)-6-(3-Methylpiperazin-1-yl)nicotinonitrile(1057682-03-7)

Safety Data

• Hazardous Substances Data: 1057682-03-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
(S)-6-(3-Methylpiperazin-1-yl)nicotinonitrile is used as a research tool for studying the role of dopamine receptors in the brain. Its selective antagonism of the D1 receptor helps scientists understand the mechanisms and functions of this receptor in various physiological and behavioral processes.
Used in Neurological and Psychiatric Disorders Treatment:
(S)-6-(3-Methylpiperazin-1-yl)nicotinonitrile is used as a potential therapeutic agent for treating neurological and psychiatric disorders. Its ability to modulate the D1 dopamine receptor has been studied for its potential role in treating conditions such as schizophrenia, Parkinson's disease, and drug addiction.
Used in Drug Development:
(S)-6-(3-Methylpiperazin-1-yl)nicotinonitrile is used as a lead compound in the development of new drugs targeting the D1 dopamine receptor. Its unique structure and pharmacological activity provide a valuable starting point for designing and optimizing novel therapeutic agents with improved efficacy and selectivity.
Used in Drug Addiction Treatment:
(S)-6-(3-Methylpiperazin-1-yl)nicotinonitrile is used as a potential treatment for drug addiction. Its ability to modulate the D1 dopamine receptor may help in reducing the rewarding effects of addictive substances and promoting recovery from addiction.
Used in Parkinson's Disease Treatment:
(S)-6-(3-Methylpiperazin-1-yl)nicotinonitrile is used as a potential therapeutic agent for treating Parkinson's disease. Its modulation of the D1 dopamine receptor may help in alleviating the motor symptoms associated with this neurodegenerative disorder.
Used in Schizophrenia Treatment:
(S)-6-(3-Methylpiperazin-1-yl)nicotinonitrile is used as a potential treatment for schizophrenia. Its selective antagonism of the D1 receptor may help in reducing the positive and negative symptoms of this psychiatric disorder, improving the quality of life for affected individuals.

Upstream product

• 33252-28-7 6-chloronicotinonitrile 
• 74879-18-8 (S)-2-methylpiperazine 

Downstream Products

• 1057677-36-7 6-[(S)-4-(4-benzylphthalazin-1-yl)-3-methylpiperazin-1-yl]nicotinonitrile 

Relevant articles and documents

POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS

The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

1-Amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity

Abnormal activation of the Hedgehog (Hh) signaling pathway has been linked to several types of human cancers, and the development of small-molecule inhibitors of this pathway represents a promising route toward novel anticancer therapeutics. A cell-based screen performed in our laboratories identified a new class of Hh pathway inhibitors, 1-amino-4-benzylphthalazines, that act via antagonism of the Smoothened receptor. A variety of analogues were synthesized and their structure-activity relationships determined. This optimization resulted in the discovery of high affinity Smoothened antagonists, one of which was further profiled in vivo. This compound displayed a good pharmacokinetic profile and also afforded tumor regression in a genetic mouse model of medulloblastoma.

ORGANIC COMPOUNDS AND THEIR USES

The present disclosure relates to compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders; specifically relating to compounds of formula (I).